10 Apr, 2012, 06:00 ET
FORT WASHINGTON, Pa., April 10, 2012 /PRNewswire/ -- ReSearch Pharmaceutical Services, Inc. (RPS), a next generation CRO that provides comprehensive global Phase 1-4 clinical development solutions to the biopharmaceutical and medical device industries, today announced the appointment of Alan Morgan as COO effective May 1st 2012.
Alan Morgan joins RPS having spent over 5 years in leadership positions with ICON plc, most recently as their Group President for Clinical Research Services. During his time at ICON, he was responsible for their global full service clinical research business, contract staffing and FSP operations, central and bioanalytical laboratories, and clinical pharmacology operations.
Alan has over 25 years experience working in both the pharmaceutical and the CRO industries. Prior to joining ICON, he was Vice President and Global General Manager of the Phase II/IV business of MDS Pharma Services, and has also held senior positions at Covance, Glaxo Wellcome and ICI Pharmaceuticals. He is a graduate of the City University in London, and a Fellow of the Chartered Association of Certified Accountants.
"Alan brings to RPS significant global expertise, with unparalleled client delivery experience in Europe and Asia. His addition will allow RPS to accelerate its goal of providing innovative clinical development solutions to the biopharmaceutical industry that improve quality and speed while driving down the cost of clinical development. We are excited to have him join the RPS management team," said Harris Koffer, Pharm.D. President.
"Combining our industry-leading Embedded model with our enhanced full-service CRO capabilities has led to attractive and sustained growth. As RPS furthers its global expansion and builds additional services and capabilities in support of our clients needs, we will continue to add expertise and leadership in developing our world class organization," concluded Daniel M. Perlman, Chairman and CEO.
Alan will work closely with Daniel M. Perlman and Harris Koffer on company strategy and operational execution in support of RPS' role as a leading provider of innovative clinical development services.
RPS provides comprehensive global Phase I-IV clinical development solutions to the Pharmaceutical, Biotechnology, Medical Device and Diagnostic industries. By combining our highly experienced clinical research operations infrastructure with the industry's largest resourcing engines, RPS is uniquely positioned to offer our Customers a broad spectrum of outsourcing solutions. These solutions range from globally Embedded functional and cross-functional programs to enhanced global full-service solutions, and are powered by highly experienced project teams providing innovative, seamless, cost-effective and high quality services.
Approaching 5,000 employees, RPS operates in more than 60 countries across the globe.
SOURCE ReSearch Pharmaceutical Services, Inc.
Share this article